How the FDA’s decision to allow the telemedical prescription of Mifepristone does (and does not) change abortion Part One: Easier for Abortionists
By Randall K. O’Bannon, Ph.D. NRL Director of Education & Research When the U.S. Food & Drug Administration (FDA) was first considering authorizing the sale of the chemical abortifacient mifepristone (also known as RU-486), reporters used to ask me all the time how I thought this would “change the abortion debate.” I tended to respond …
Continue reading "How the FDA’s decision to allow the telemedical prescription of Mifepristone does (and does not) change abortion Part One: Easier for Abortionists"